The Expansion of Immunobiologics Manufacturing in Latin America

Latin America is transforming from a consumer to a global hub for immunobiologics, driven by modernized infrastructure, skilled talent, regulatory harmonization, and a focus on regional health self-sufficiency.

Life Sciences Review | Wednesday, March 04, 2026

Latin America is emerging as a key player in immunobiological manufacturing. Previously seen mainly as a consumer market, the region is now becoming a strategic hub for producing vaccines, monoclonal antibodies, and advanced recombinant proteins. This transformation is fueled by technological modernization, specialized talent, and a shared commitment to health sovereignty.

Technological Modernization and Infrastructure Expansion

Latin America’s progress in immunobiologics relies on the large-scale modernization of its industrial infrastructure. Across the region, outdated manufacturing facilities are being replaced or upgraded with advanced bioprocessing plants that meet the demands of modern biological products. This shift demonstrates a commitment to globally competitive production, fostering innovation and scalability.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

A key aspect of this modernization is the adoption of flexible, modular manufacturing platforms. These systems allow rapid scaling and reconfiguration to meet changing public health needs, while avoiding the long lead times and high capital costs of traditional fixed stainless-steel facilities. The integration of single-use technologies has also become standard in new developments. Single-use systems reduce cross-contamination risks, simplify changeovers, and help lower the environmental impact of large-scale operations.

Technological investment in the region now extends beyond conventional inactivated vaccines to include advanced biopharmaceutical platforms. Regional hubs for messenger RNA research and manufacturing have been established, supporting infectious disease prevention and new applications in oncology and personalized medicine. These developments position Latin America as a key participant in the global mRNA innovation ecosystem.

Infrastructure for monoclonal antibody production is expanding rapidly. As monoclonal antibodies represent most regional biotechnology demand, new facilities feature high-capacity mammalian cell culture bioreactors and advanced purification systems. This growth enhances the region’s capacity to produce complex biologics at scale and meet international quality and regulatory standards.

Investment in viral vector and recombinant protein platforms is increasing. These capabilities are essential for developing next-generation therapies, such as gene therapies and advanced protein-based treatments. Expanding capacity in these areas helps the region build a more diversified and resilient biomanufacturing ecosystem.

Alongside these physical and technological upgrades, manufacturing digitalization, often called Bioprocessing 4.0, is advancing rapidly. AI-enabled process analytical technologies now enable real-time monitoring and control of biological processes, improving yields, consistency, and quality. This digital transformation is essential for maintaining cost competitiveness and meeting strict international standards, strengthening Latin America’s position in the global immunobiologics sector.

Strategic Investment and Workforce Development

Alongside expanding physical infrastructure, Latin America is making significant investments in intellectual infrastructure. The region now features a sophisticated network of research universities, government-supported science parks, and private investment hubs that drive innovation from early-stage research to commercial production.

The growth of the immunobiological sector depends on developing specialized human capital. Efforts are focused on building a workforce skilled in molecular biology, bioinformatics, and regulatory science. Academic institutions are updating postgraduate programs in biotechnology and biomanufacturing to meet industry needs. Regional technical centers provide practical training in Good Manufacturing Practices, cleanroom operations, and advanced analytical techniques such as chromatography. These efforts are reinforced by a sustained “brain gain,” as internationally experienced scientists return to lead research centers and share global best practices and networks.

Capital inflows into the sector have reached a critical threshold. Public funding remains catalytic, while private equity and venture capital investment in biotechnology startups continue to grow. This convergence is fostering bioclusters, which are geographically concentrated ecosystems where startups, manufacturers, and research institutions collaborate to accelerate the development and commercialization of new therapies.

These bioclusters are characterized by strong collaboration. The sector is adopting open innovation, shared infrastructure, and co-development frameworks to reduce development time and costs. This approach now defines Latin American biotechnology, emphasizing regional capability over isolated efforts.

Regulatory Convergence and Regional Self-Sufficiency

Regulatory harmonization is a key factor driving sustained growth in immunobiological manufacturing across Latin America. To ensure the sector’s maturity and competitiveness, products must be recognized and accepted regionally and internationally. As national regulatory authorities align with global standards, confidence in regional manufacturing is expected to increase.

Regional initiatives play a key role in harmonization. Organizations such as the Pan American Network for Drug Regulatory Harmonization (PANDRH) and other multilateral bodies are creating a more unified regulatory environment. The expansion of Mutual Recognition Agreements and regulatory reliance models allows authorities to use assessments from trusted regional partners, which speeds up approval timelines while maintaining safety and quality. Aligning Good Manufacturing Practice certification standards is improving consistency in inspections and helping facilities meet international export requirements. The broader use of electronic Common Technical Documents is also modernizing regulatory processes by standardizing digital submissions, reducing administrative burdens, and supporting simultaneous market entry in multiple jurisdictions.

Together, these reforms advance a strategic goal beyond regulatory efficiency: building sovereign and resilient supply chains. Regional self-sufficiency in immunobiologics production is now seen as essential for public health security. This goal includes not only manufacturing the final product but also developing reliable regional sources for critical inputs such as enzymes, lipids, and specialized cell culture media. Strengthening these upstream capabilities reduces external dependencies and improves the region’s capacity to meet public health needs.

Market indicators highlight the importance of this transition. The Latin American market for vaccines and antibody-based therapies is expected to grow significantly over the next decade. By 2030, monoclonal antibody manufacturing in the region is projected to exceed USD 1 billion, with a compound annual growth rate of nearly 10 percent. This growth signals a shift toward sustainable, regionally focused production models that address local healthcare needs and establish Latin America as a competitive global supplier of high-quality, cost-effective biologics.

As the industry matures, attention is shifting to the future of "South-South" cooperation. By sharing technology, regulatory expertise, and manufacturing capacity, Latin American nations are forming a strong presence in the global biopharmaceutical sector. This growth reflects a commitment to excellence, collaboration, and the technological capacity to address the complex medical challenges of the 21st century.

More in News

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Specials

The Expansion of Immunobiologics Manufacturing in Latin America

Latin America is transforming from a consumer to a global hub for immunobiologics, driven by modernized infrastructure, skilled talent, regulatory harmonization, and a focus on regional health self-sufficiency.